Aethlon gets $6.8M DARPA contract; Abbott begins enrolling U.S. patients in EXCEL study;

> Aethlon Medical ($AEMD) has been awarded a $6.8 million contract from DARPA to develop a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection that is often the cause of death in combat-injured soldiers. Aethlon release

> Abbott ($ABT) has begun enrolling U.S. patients in the EXCEL trial to assess the safety and efficacy of the XIENCE PRIME/XIENCE V everolimus-eluting coronary stent systems versus coronary artery bypass grafting or surgery in select patients with unprotected left main coronary artery disease. Abbott release

> Precision Engineered Products has purchased Boston Endo-Surgical Technologies, a manufacturer of spinal and orthopedic surgical instruments. The newly acquired company will be integrated into PEP's Lacey business unit, based in Bridgeport, CT. PEP release

> Bryan McMillan has been promoted to president of Orthofix International's ($OFIX) Spine Global Business unit. Orthofix release

> Cynosure ($CYNO) has acquired worldwide exclusive rights to distribute the PinPointe FootLaser from NuvoLase. Cynosure release

> Boston Scientific ($BSX) has started enrollment in a study to evaluate the safety and effectiveness of its OMEGA platinum chromium bare-metal coronary stent system in treating patients with a single coronary artery lesion. Boston Scientific release

And Finally... A family that owns land near a plant operated by Baxter International in Puerto Rico is suing the company for $50 million, alleging their property was contaminated with radioactive cobalt and other potentially hazardous materials. News

Suggested Articles

A decade-long study found that patients with early breast cancer may be spared radiation procedures that span the whole breast.

A cell therapy for Parkinson’s disease starts out simple, but quickly gets complicated with the potential for immune responses and cancer mutations.

Johnson & Johnson Vision announced that the worldwide president of its surgical business, Tom Frinzi, plans to retire at the end of this year.